ADC Therapeutics competes within the highly competitive oncology and antibody-drug conjugate pharmaceutical space against numerous specialized biotechnology and global pharmaceutical giants. Prominent industry peers engaged in developing targeted cancer therapies and ADC platforms include companies such as Seagen (Pfizer), ImmunoGen (AbbVie), Gilead Sciences, Daiichi Sankyo, AstraZeneca, and other innovative oncology-focused biotech firms advancing targeted cancer treatments.